Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 5.3%

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) were down 5.3% on Wednesday . The stock traded as low as $1.08 and last traded at $1.08. Approximately 126,750 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 1,761,175 shares. The stock had previously closed at $1.14.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Adaptimmune Therapeutics in a report on Friday, December 29th. They issued a “hold” rating for the company.

Adaptimmune Therapeutics Stock Performance

The company has a 50-day moving average of $1.39 and a 200-day moving average of $0.92.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.12). The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $4.80 million. Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. Equities analysts predict that Adaptimmune Therapeutics plc will post -0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Barclays PLC acquired a new position in shares of Adaptimmune Therapeutics in the second quarter valued at about $46,000. Marquette Asset Management LLC purchased a new stake in shares of Adaptimmune Therapeutics in the third quarter worth about $77,000. Key Client Fiduciary Advisors LLC boosted its stake in shares of Adaptimmune Therapeutics by 6.4% in the fourth quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock worth $267,000 after buying an additional 20,295 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in Adaptimmune Therapeutics by 9.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 13,317 shares in the last quarter. Finally, Acuitas Investments LLC purchased a new position in Adaptimmune Therapeutics during the third quarter worth approximately $374,000. 31.37% of the stock is owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.